{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T22:50:54Z","timestamp":1779403854210,"version":"3.53.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.molmed.2005.04.006","type":"journal-article","created":{"date-parts":[[2005,5,12]],"date-time":"2005-05-12T11:45:26Z","timestamp":1115898326000},"page":"299-305","source":"Crossref","is-referenced-by-count":30,"title":["Emerging therapeutic approaches for osteogenesis imperfecta"],"prefix":"10.1016","volume":"11","author":[{"given":"Sophia","family":"Millington-Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena P.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Jane","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2005.04.006_bib1","first-page":"508","article-title":"Osteogenesis imperfecta type I is commonly due to a COL1A1 null allele of type I collagen","volume":"51","author":"Willing","year":"1992","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2005.04.006_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ajmg.1320450214","article-title":"Molecular heterogeneity in osteogenesis imperfecta type I","volume":"45","author":"Willing","year":"1993","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.molmed.2005.04.006_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.molmed.2005.04.006_bib4","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2005.04.006_bib5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","article-title":"Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta","volume":"16","author":"Devogelaer","year":"1987","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.molmed.2005.04.006_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s002230010045","article-title":"A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta","volume":"69","author":"Camacho","year":"2001","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.molmed.2005.04.006_bib7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2005.04.006_bib8","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.85.5.1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","author":"Plotkin","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2005.04.006_bib9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","article-title":"Do bisphosphonates make children's bones better or brittle?","volume":"349","author":"Marini","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2005.04.006_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1582-4934.2004.tb00320.x","article-title":"Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy","volume":"8","author":"Baksh","year":"2004","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.molmed.2005.04.006_bib11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.1088757","article-title":"Gene targeting in stem cells from individuals with osteogenesis imperfecta","volume":"303","author":"Chamberlain","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.molmed.2005.04.006_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/332131a0","article-title":"Perinatal lethal osteogenesis imperfecta in transgenic mice bearing an engineered mutant pro-\u03b11(I) collagen gene","volume":"332","author":"Stacey","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2005.04.006_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/304315a0","article-title":"Embryonic lethal mutation in mice induced by retrovirus insertion into the \u03b11(I) collagen gene","volume":"304","author":"Schnieke","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2005.04.006_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0092-8674(83)90511-1","article-title":"Germline integration of moloney murine leukemia virus at the Mov13 locus leads to recessive lethal mutation and early embryonic death","volume":"32","author":"Jaenisch","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2005.04.006_bib15","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1073\/pnas.87.18.7145","article-title":"Transgenic mouse model of the mild dominant form of osteogenesis imperfecta","volume":"87","author":"Bonadio","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2005.04.006_bib16","doi-asserted-by":"crossref","first-page":"37923","DOI":"10.1074\/jbc.274.53.37923","article-title":"Use of the Cre\/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an \u03b11(I) G349C substitution. Variability in phenotype in BrtlIV mice","volume":"274","author":"Forlino","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2005.04.006_bib17","doi-asserted-by":"crossref","first-page":"23373","DOI":"10.1016\/S0021-9258(18)54506-3","article-title":"Transgenic mice that express a mini-gene version of the human gene for type I procollagen (COL1A1) develop a phenotype resembling a lethal form of osteogenesis imperfecta","volume":"266","author":"Khillan","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"Suppl. 2","key":"10.1016\/j.molmed.2005.04.006_bib18","doi-asserted-by":"crossref","first-page":"S489","DOI":"10.1002\/jbmr.5650081311","article-title":"Mutations in type 1 procollagen that cause osteogenesis imperfecta: effects of the mutations on the assembly of collagen into fibrils, the basis of phenotypic variations, and potential antisense therapies","volume":"8","author":"Prockop","year":"1993","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.molmed.2005.04.006_bib19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S8756-3282(96)00305-5","article-title":"Heterozygous oim mice exhibit a mild form of osteogenesis imperfecta","volume":"19","author":"Saban","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.molmed.2005.04.006_bib20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1354\/vp.40-5-530","article-title":"Osteogenesis imperfecta in two litters of dachshunds","volume":"40","author":"Seeliger","year":"2003","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.molmed.2005.04.006_bib21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.biocel.2003.11.001","article-title":"Mesenchymal stem cells: clinical applications and biological characterization","volume":"36","author":"Barry","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.molmed.2005.04.006_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells","volume":"284","author":"Pittenger","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.molmed.2005.04.006_bib23","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/81395","article-title":"Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep","volume":"6","author":"Liechty","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2005.04.006_bib24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/01.TP.0000128334.93343.B3","article-title":"Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice","volume":"78","author":"Allers","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.molmed.2005.04.006_bib25","doi-asserted-by":"crossref","unstructured":"Mosca, J.D. et al. (2000) Mesenchymal stem cells as vehicles for gene delivery. Clin. Orthop. Relat. Res. (397 Suppl.), S71\u2013S90","DOI":"10.1097\/00003086-200010001-00011"},{"key":"10.1016\/j.molmed.2005.04.006_bib26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/sj.leu.2402763","article-title":"Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture","volume":"17","author":"Rombouts","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2005.04.006_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2005.04.006_bib28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.exphem.2004.02.010","article-title":"Studies of the route of administration and role of conditioning with radiation on unrelated allogeneic mismatched mesenchymal stem cell engraftment in a nonhuman primate model","volume":"32","author":"Mahmud","year":"2004","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.molmed.2005.04.006_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF02256058","article-title":"Characterization and functionality of cell surface molecules on human mesenchymal stem cells","volume":"10","author":"Majumdar","year":"2003","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.molmed.2005.04.006_bib30","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1073\/pnas.95.3.1142","article-title":"Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta","volume":"95","author":"Pereira","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2005.04.006_bib31","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1073\/pnas.92.11.4857","article-title":"Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice","volume":"92","author":"Pereira","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2005.04.006_bib32","doi-asserted-by":"crossref","first-page":"8932","DOI":"10.1073\/pnas.132252399","article-title":"Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone","volume":"99","author":"Horwitz","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2005.04.006_bib33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1073\/pnas.84.3.764","article-title":"Introduction of the human pro \u03b11(I) collagen gene into pro \u03b11(I)-deficient Mov-13 mouse cells leads to formation of functional mouse\u2013human hybrid type I collagen","volume":"84","author":"Schnieke","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2005.04.006_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/jcb.1209","article-title":"Transfer of pro-\u03b12(I) cDNA into cells of a murine model of human Osteogenesis Imperfecta restores synthesis of type I collagen comprised of \u03b11(I) and \u03b12(I) heterotrimers in vitro and in vivo","volume":"83","author":"Niyibizi","year":"2001","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.molmed.2005.04.006_bib35","doi-asserted-by":"crossref","first-page":"11033","DOI":"10.1021\/bi00202a024","article-title":"Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA","volume":"33","author":"Laptev","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.molmed.2005.04.006_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1021\/bi00052a002","article-title":"Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells","volume":"32","author":"Colige","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.molmed.2005.04.006_bib37","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/sj.gt.3302108","article-title":"Enhanced intracellular availability and survival of hammerhead ribozymes increases target ablation in a cellular model of osteogenesis imperfecta","volume":"10","author":"Smicun","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2005.04.006_bib38","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/hmg\/11.19.2201","article-title":"Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta","volume":"11","author":"Millington-Ward","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2005.04.006_bib39","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1093\/nar\/25.17.3451","article-title":"Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects","volume":"25","author":"Grassi","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molmed.2005.04.006_bib40","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.ejhg.5201230","article-title":"RNAi of COL1A1 in mesenchymal progenitor cells","volume":"12","author":"Millington-Ward","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2005.04.006_bib41","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1073\/pnas.91.14.6298","article-title":"Partial rescue of a lethal phenotype of fragile bones in transgenic mice with a chimeric antisense gene directed against a mutated collagen gene","volume":"91","author":"Khillan","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2005.04.006_bib42","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI118434","article-title":"Antisense oligodeoxynucleotides selectively suppress expression of the mutant \u03b12(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders","volume":"97","author":"Wang","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2005.04.006_bib43","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1042\/bst0301162","article-title":"Ribozymes, the first 20 years","volume":"30","author":"Cech","year":"2002","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.molmed.2005.04.006_bib44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/108729001753231722","article-title":"Delivery of a hammerhead ribozyme specifically downregulates mutant type I collagen mRNA in a murine model of osteogenesis imperfecta","volume":"11","author":"Toudjarska","year":"2001","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.molmed.2005.04.006_bib45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrm1129","article-title":"Killing the messenger: short RNAs that silence gene expression","volume":"4","author":"Dykxhoorn","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.molmed.2005.04.006_bib46","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/hmg\/6.9.1415","article-title":"Strategems in vitro for gene therapies directed to dominant mutations","volume":"6","author":"Millington-Ward","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2005.04.006_bib47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/oli.1.1999.9.537","article-title":"A mutation-independent therapeutic strategem for osteogenesis imperfecta","volume":"9","author":"Millington-Ward","year":"1999","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.molmed.2005.04.006_bib48","first-page":"2863","article-title":"Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa","volume":"41","author":"O'Neill","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.molmed.2005.04.006_bib49","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1002\/jgm.498","article-title":"Toolbox for retrovectorologists","volume":"6","author":"Pages","year":"2004","journal-title":"J. Gene Med."},{"key":"10.1016\/j.molmed.2005.04.006_bib50","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1089\/hum.1997.8.12-1417","article-title":"LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors","volume":"8","author":"Allay","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2005.04.006_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/viro.2001.0903","article-title":"Use of VSV-G pseudotyped retroviral vectors to target murine osteoprogenitor Cells","volume":"284","author":"Kalajzic","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.molmed.2005.04.006_bib52","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1128\/JVI.78.3.1219-1229.2004","article-title":"Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins","volume":"78","author":"Zhang","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2005.04.006_bib53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/sj.gt.3300839","article-title":"Retrovirally transduced bone marrow stromal cells isolated from a mouse model of human osteogenesis imperfecta (oim) persist in bone and retain the ability to form cartilage and bone after extended passaging","volume":"6","author":"Oyama","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2005.04.006_bib54","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/sj.gt.3302199","article-title":"Gene therapy approaches for osteogenesis imperfecta","volume":"11","author":"Niyibizi","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2005.04.006_bib55","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1126\/science.1068893","article-title":"Murine leukemia induced by retroviral gene marking","volume":"296","author":"Li","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.molmed.2005.04.006_bib56","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.molmed.2005.04.006_bib57","doi-asserted-by":"crossref","unstructured":"Volpers, C. and Kochanek, S. (2004) Adenoviral vectors for gene transfer and therapy. J. Gene Med. (Suppl. 1), S164\u2013S171","DOI":"10.1002\/jgm.496"},{"key":"10.1016\/j.molmed.2005.04.006_bib58","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.gt.3302298","article-title":"Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery","volume":"11","author":"Kang","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2005.04.006_bib59","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/1097-4644(20000901)78:3<476::AID-JCB12>3.0.CO;2-5","article-title":"Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7","volume":"78","author":"Franceschi","year":"2000","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.molmed.2005.04.006_bib60","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/107632703764664819","article-title":"Human mesenchymal stem cells transduced with recombinant bone morphogenetic protein-9 adenovirus promote osteogenesis in rodents","volume":"9","author":"Dayoub","year":"2003","journal-title":"Tissue Eng."},{"key":"10.1016\/j.molmed.2005.04.006_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0167-7799(02)00042-2","article-title":"Latest development in viral vectors for gene therapy","volume":"21","author":"Lundstrom","year":"2003","journal-title":"Trends Biotechnol."},{"issue":"Suppl. 1","key":"10.1016\/j.molmed.2005.04.006_bib62","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/jgm.507","article-title":"Gene transfer with modified polyethylenimines","volume":"6","author":"Kichler","year":"2004","journal-title":"J. Gene Med."},{"key":"10.1016\/j.molmed.2005.04.006_bib63","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2174\/0929867033457458","article-title":"Cationic transfection lipids in gene therapy: successes, set-backs, challenges and promises","volume":"10","author":"Kumar","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.molmed.2005.04.006_bib64","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/sj.gt.3302163","article-title":"Stable transfection of MSCs by electroporation","volume":"11","author":"Peister","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2005.04.006_bib65","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jmb.2003.09.082","article-title":"Phage integrases: biology and applications","volume":"335","author":"Groth","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.molmed.2005.04.006_bib66","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1073\/pnas.090527097","article-title":"A phage integrase directs efficient site-specific integration in human cells","volume":"97","author":"Groth","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2005.04.006_bib67","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.1073\/pnas.1432929100","article-title":"Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects","volume":"100","author":"Ortiz","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2005.04.006_bib68","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ymthe.2004.05.034","article-title":"Nucleofection of muscle-derived stem cells and myoblasts with \u03d5C31 integrase: stable expression of a full-length-dystrophin fusion gene by human myoblasts","volume":"10","author":"Quenneville","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2005.04.006_bib69","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1634\/stemcells.22-3-324","article-title":"Transfer and stable transgene expression of a mammalian artificial chromosome into bone marrow-derived human mesenchymal stem cells","volume":"22","author":"Vanderbyl","year":"2004","journal-title":"Stem Cells"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491405000973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491405000973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T06:49:09Z","timestamp":1735714149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491405000973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S1471491405000973"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2005.04.006","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}